Gemcitabine(G)/erlotinib(E) versus gemcitabine/erlotinib/capecitabine(C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from the Spanish TTD Collaborative Group

Authors Benavides, M., Plazas, J.G., Guillen, C., Vera, R., Iranzo, V., Diaz, I.A. -More
Category Primary study
JournalJournal of Clinical Oncology
Year 2014
Links
This article has no abstract
Epistemonikos ID: 16f7cb04ba4d86e7fb464ebe67ad1865216fd915
First added on: Feb 06, 2025